Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China; Key Laboratory of Gene Function and Regulation of the Ministry of Education, School of Life Sciences, Sun Yat-sen University, Guangzhou, 510275, China.
Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Cancer Lett. 2024 Mar 31;585:216638. doi: 10.1016/j.canlet.2024.216638. Epub 2024 Jan 22.
Recent studies have suggested that therapeutic upregulation of CCAAT/enhancer binding protein α (C/EBPα) prevents hepatocellular carcinoma (HCC) progression. However, the mechanisms underlying this outcome are not fully understood. In this study, we investigated the expression and functional roles of C/EBPα in human HCC, with a focus on monocytes/macrophages (Mφs). Paraffin-embedded tissues were used to visualize C/EBPα expression and analyze the prognostic value of C/EBPα monocytes/Mφs in HCC patients. The underlying regulatory mechanisms were examined using human monocyte-derived Mφs. The results showed that the expression of C/EBPα on monocytes/Mφs was significantly decreased in intra-tumor tissues compared to the corresponding peri-tumor tissues. C/EBPα monocytes/Mφs displayed well-differentiation and antitumor capacities, and the accumulation of these cells in tissue was associated with antitumor immune responses and predicted longer overall survival (OS) of HCC patients. Mechanistic studies demonstrated that C/EBPα was required for Mφ maturation and HLA-DR, CD169 and CD86 expression, which initiates antitumor cytotoxic T-cell responses; however, these effects were inhibited by monocyte autocrine IL-6- and IL-1β-induced suppression of mTOR1 signaling. Reprogramming Mφs via the upregulation of C/EBPα may provide a novel strategy for cancer immunotherapy in patients with HCC.
最近的研究表明,CCAAT/增强子结合蛋白α(C/EBPα)的治疗性上调可预防肝细胞癌(HCC)的进展。然而,其具体作用机制尚不完全清楚。在本研究中,我们研究了 C/EBPα在人 HCC 中的表达和功能作用,重点关注单核细胞/巨噬细胞(Mφs)。我们使用石蜡包埋组织来可视化 C/EBPα的表达,并分析 C/EBPα单核细胞/Mφs 在 HCC 患者中的预后价值。我们使用人单核细胞衍生的 Mφs 来研究潜在的调控机制。结果表明,与相应的肿瘤周围组织相比,肿瘤内组织中单核细胞/Mφs 上 C/EBPα的表达明显降低。C/EBPα单核细胞/Mφs 具有良好的分化和抗肿瘤能力,这些细胞在组织中的积累与抗肿瘤免疫反应有关,并预测 HCC 患者的总生存期(OS)更长。机制研究表明,C/EBPα是 Mφ 成熟和 HLA-DR、CD169 和 CD86 表达所必需的,这会引发抗肿瘤细胞毒性 T 细胞反应;然而,单核细胞自分泌的 IL-6 和 IL-1β 诱导的 mTOR1 信号抑制会抑制这些作用。通过上调 C/EBPα 重编程 Mφs 可能为 HCC 患者的癌症免疫治疗提供一种新策略。